Raymond James Reinstates Outperform on Regenxbio, Announces $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has reinstated an Outperform rating on Regenxbio (NASDAQ:RGNX) and set a price target of $18.
October 10, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James has reinstated an Outperform rating on Regenxbio with a price target of $18, indicating a positive outlook for the stock.
The reinstatement of an Outperform rating by a reputable analyst and the setting of a price target at $18 suggests a positive short-term impact on Regenxbio's stock price. This indicates confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100